Institute for Personalised Medicine in Croatia ranks third in the world in precision tumour testing

Institute for Personalised Medicine in Zagreb (Photo: KBC Zagreb)

ZAGREB, 15 April 2026 – Croatia has positioned itself among global leaders in cancer diagnostics, with the Institute for Personalised Medicine ranked third in the world for precision tumour testing, HRT reported.

The institute, based in the Croatian capital Zagreb, has become a key centre for advanced molecular diagnostics, offering patients access to some of the most modern genomic testing available today.

Advanced diagnostics enabling targeted therapy

The institute specialises in molecular profiling of tumours, allowing doctors to tailor therapies to individual patients. This approach, known as targeted therapy, is particularly important for those with metastatic or advanced, inoperable cancers.

In 2025 alone, around 2,500 tumour samples were analysed by a multidisciplinary team of doctors, pathologists, laboratory engineers and molecular biologists.

Patients typically receive results within 14 days, enabling quicker and more precise treatment decisions.

Real-life impact on patients

For patients targeted therapy has made a significant difference. Living with metastatic breast cancer for nine years, one patient highlighted the progress made in treatment.

Her case illustrates how advanced diagnostics can extend survival and improve quality of life, even in cases diagnosed at an advanced stage.

Broad access to genomic profiling

According to Natalija Dedić Plavetić of University Hospital Centre Zagreb, eligibility for comprehensive genomic profiling depends on clinical indications set by oncologists and multidisciplinary teams.

In practice, this means that a wide range of patients may benefit, depending on their diagnosis and stage of disease.

Expanding genomic technologies

The institute is also working to expand its diagnostic capabilities beyond traditional tissue analysis. Plans include broader use of liquid biopsy techniques and other advanced genomic technologies.

Kristina Gotovac Jerčić, head of next-generation sequencing, emphasised the goal of providing patients with access to a wider range of cutting-edge tests.

In just two years, the institute has evolved into a central hub for diagnosing not only cancer but also other diseases. Despite having a team of just 18 staff, its impact has been significant.

According to Fran Borovečki, only institutions in Australia and Israel ranked higher globally last year.

Cancer increasingly becoming a chronic condition

Advances in diagnostics and treatment are changing the nature of cancer care. As noted by Marija Bubaš, cancer is increasingly being managed as a chronic disease.

Nearly 200,000 people in Croatia are currently living with or have been diagnosed with cancer, underlining the importance of continued innovation in oncology.

Looking ahead, Croatia plans to further strengthen its cancer care system. A national oncology network and centralised database are expected to be completed by the end of the year, improving coordination and patient outcomes across the country.